‘Holy grail' diet pill burns fat without affecting appetite or muscle mass unlike weight loss jabs
A diet pill that lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass, could help patients lose weight without suffering brutal side effects.
The potential new drug treatment for people with type 2 diabetes and obesity, which is taken in tablet form, works in a completely different way to GLP-1 injections such as Ozempic and Wegovy.
These injections work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
These injections affect the hunger signals between the gut and the brain, but can often cause a loss of appetite, reduced muscle mass and gastrointestinal problems – leaving people feeling weaker or saggy.
However, the new drug works by triggering the metabolism in the muscles, activating them to burn more fat.
In animal studies, the treatment has shown good effects on both blood sugar control and body composition, but without the side effects associated with today's GLP-1-based drugs.
The study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University, revealed an initial clinical trial involving 48 healthy participants and 25 people with type 2 diabetes found humans can also tolerate the treatment.
"Our results point to a future where we can improve metabolic health without losing muscle mass. Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy," said one of the researchers behind the study, Tore Bengtsson, professor at the Department of Molecular Bioscience, Wenner-Gren Institute, Stockholm University.
The drug is based on a substance – a type of β2 (beta) agonist – which researchers have developed in a lab. Beta 2 agonist drugs are commonly used to treat asthma, but they can cause side-effects such as an increased heart rate or tremors.
Researchers say the molecule they created has a positive effect on the muscles without overstimulating the heart.
'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity. Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections," said Shane Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet, who is one of the researchers behind the study.
The next step for researchers is a clinical study planned by Atrogi AB, the company developing the treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
6 hours ago
- The Independent
The three lifestyle factors putting a million UK adults at risk of dying early
About a million people in England are putting themselves at risk of dying early because they are overweight and combine drinking too much and smoking, research has found. The 'triple threat' disproportionately raises their risk of diseases including cancer, heart disease, stroke, Type-2 diabetes, liver disease and mental health conditions, experts warn. One doctor said the combination may cut 20 years from someone's life. Analysis of a Health Survey for England by charity Action on Smoking and Health (Ash) found that 22 per cent of adults in England – at least 10 million people – have two or more of the three risk factors. About 2 per cent – a million adults – fall into all three categories. Public-health experts warned two years ago that high levels of obesity, excessive drinking and health inequalities were costing the economy £15bn a year. Professor Sir Ian Gilmore, chairman of the Alcohol Health Alliance, said each of the three habits carried a risk, but when combined the danger is exaggerated. 'These poor health outcomes are not only avoidable, but they also place a huge and growing strain on the NHS and our economy,' he said. "We urgently need a joined-up approach to public health policymaking that tackles these issues together, rather than in isolation, if we are to see the much-needed governmental shift from sickness to prevention.' The combined effects of smoking, drinking and being overweight are often greater than the sum of individual risks, studies have shown. The new analysis of 2021 data also found that: ● 5.9 million people (13 per cent of adults) have factors of being overweight or obesity and drinking ● 2.5 million (6 per cent of adults) are overweight or obese and smoke ● 0.6 million (1 per cent of adults) drink and smoke without being overweight Prof Gilmore, a former president of the Royal College of Physicians, told The Guardian it was likely that smoking, grade three obesity and heavy drinking would reduce life expectancy by at least 20 years. Katharine Jenner, director of the Obesity Health Alliance, said: 'These are not issues of individual behaviour, but issues of industry behaviour or tactics. 'Behind the statistics on smoking, alcohol and unhealthy food-related disease lie multi-million-pound industries that operate in darkly similar ways – producing, marketing and selling products that damage our wellbeing. 'The government will not be able to meet its ambition of shifting from prevention to treatment until it recognises this.' Caroline Cerny, the deputy chief executive of Ash, said the government's forthcoming 10-year plan was an opportunity to 'get a firm grip on the causes of ill health that are shortening the lives of people and placing a huge strain on the NHS'. She called for targets to cut smoking, drinking and excess weight, introducing minimum-unit pricing of alcohol in England and extending the sugar tax. Health secretary Wes Streeting is next week due to unveil his 10-year plan for the NHS, aimed at tackling inequalities through fundamental reforms, and measures such as sending health workers door-to-door. People will be urged to monitor their own health with technology such as smart watches that monitor blood pressure and glucose levels. The Department of Health and Social Care was approached for comment but a spokesperson told The Guardian ministers were committed to tackling obesity through a ban on the advertising of junk food on television before 9pm and a planned new food strategy. They also an extra £310m had been put to treatment of drug and alcohol addiction, while the Tobacco and Vapes Bill phases out the sale of cigarettes.
The Sun
9 hours ago
- The Sun
New Ozempic alternative only needs to be taken once a month and leads to ‘substantial weight loss'
A NEW weight loss jab that only needs to be taken once monthly leads to "substantial weight loss", according to early trials. Drugs like Wegovy and Mounjaro - or diabetes jab Ozempic - need to be injected once weekly to see results. 1 But a new drug currently being trialled by pharmaceutical company Amgen can be given once a month and saw users shed up to 16 per cent of their body weight over the course of a year. This is bellow the 20 per cent weight loss than can be achieved through Mounjaro - dubbed the 'King Kong' of weight loss jabs - over 18 months. But scientists behind the new trial said the less frequent dose schedule could encourage people to stick to the treatment. The drug is called maridebart cafraglutide, or MariTide for short. Like Wegoy, Mounjaro and Ozempic, it's a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it targets the GLP-1 receptors in the brain and pancreas to reduce appetite and control blood sugar. But it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors, which are also involved in managing insulin release, fat storage, metabolism, and appetite. This is part of the reason the drug needs to be administered less often. "In this phase two trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes," they wrote in The New England Journal of Medicine. "Once-monthly therapeutics for obesity may offer sustainable treatment for persons with this highly prevalent, chronic disease. "Medication at less frequent intervals may improve adherence and reduce barriers, potentially facilitating improvements in long-term health outcomes." There were 592 people aged 18 or older enrolled in the study - 465 of them were obese, defined as having a BMI of 30 or more, or a BMI of 27 with one obesity-related complication. The remaining participants had obesity as well as type 2 diabetes. They were randomly given monthly maridebart cafraglutide injections or a placebo for a year, at dose of 140, 280, or 420 mg. Some participants remained on a stable dose throughout, while others gradually worked up to a higher one. Participants were asked to report any side effects they experienced from the drug, such as nausea, vomiting, retching, headaches, diarrhoea and constipation Those with obesity lost 12.3 to 16.2 per cent of their body weight while taking maridebart cafraglutide over 52 weeks, compared to people taking a placebo who only lost 2.5 per cent of their weight. As for people with diabetes and obesity, they lost 8.4 to 12.3 per cent of their body weight on the drug, compared to 1.7 per cent weight loss for placebo-takers. Almost all participants taking maridebart cafraglutide experienced at least one side-effect from the drug - mild to moderate nausea, vomiting and retching were the most frequently reported side-effects. These effects were less severe when participants gradually built up to a full dose of maridebart cafraglutide, which may be the best way to get people started on it in the future. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Two deaths were reported in participants who received maridebart cafraglutide, but both were investigated and deemed unrelated to the drug. A handful of people taking the drug reported gallbladder issues, which can also be an issue with other weight loss jabs. Some also experienced depression and suicidal thoughts while participating in the trial. One person taking maridebart cafraglutide and one person on the placebo drug withdrew as a result. This was a phase two clinical trial, meaning it still needs to be tested on a bigger group of participants over a longer time period. Amgen deemed the results promising enough to progress to a phase three trial. "This phase two dose-ranging trial investigating the efficacy and safety of maridebart cafraglutide, a long-acting GLP-1 receptor agonist and GIP receptor antagonist administered once monthly or less frequently, showed substantial weight reduction and no new or unexpected safety signals, supporting advancement to phase three," researchers wrote. They estimated MariTide could lead to even more weight loss, beyond a year of use. they noted.
The Guardian
10 hours ago
- The Guardian
Smoking, drinking too much and being overweight ‘puts one in 50 adults in England at risk of early death'
One in 50 people aged 16 or older in England is at risk of an early death because they smoke, drink too much and are overweight, research has found. This 'triple threat' increases the risk of diseases such as cancer and diabetes and in some cases dying as much as 20 years earlier than they should, a senior doctor has said. About 1 million people in England are living with that threat, an analysis of the Health Survey for England by the charity Action on Smoking and Health (Ash) revealed. They are the 2.2% of the population who use tobacco, drink more than 14 units of alcohol a week and are overweight or obese, as judged by having a body mass index (BMI) of 25 or more. However, 10 million – 22% of the population – exhibit two of the three risky behaviours, Ash found, while 33.9 million (73.6%) have at least one risk factor. Prof Sir Ian Gilmore, the chair of the Alcohol Health Alliance, said: 'It is staggering that as many as one in 50 adults in England are at a much higher risk of dying because of the combination of tobacco, alcohol and unhealthy food. 'Smoking, alcohol and excess weight each significantly increase the risk of serious health problems like cancer, heart disease and liver disease. When these risk factors are combined, the danger to people's health is even greater, leading to higher chances of early death and more years in poor health. 'Together they create a toxic combination that can lead to long-term disability and early death.' A lifelong smoking habit reduces someone's life expectancy by about 10 years and grade three obesity – being severely obese with a BMI of more than 40 – does so by a similar amount. The UK's four chief medical officers recommend that no one drinks more than 14 units of alcohol a week. Gilmore, a former president of the Royal College of Physicians, added: 'Although the risks of two or more risk factors are not purely additive, it is likely that smoking, grade three obesity and heavy drinking will reduce life expectancy by at least 20 years.' Ash also found that: 12.7% of people in England (5.9 million) are overweight and drink more than 14 units but do not smoke. 5.5% (2.5 million) are overweight and smoke but drink less than 14 units. 1.4% (600,000) smoke and drink more than 14 units but have a normal weight. Caroline Cerny, the deputy chief executive of Ash, said: 'The findings are extremely worrying. They provide an insight into the challenges facing the NHS both now and in the future.' The burden of illness in England is rising due to the ageing and growing population and impact of lifestyle-related conditions linked to smoking, drinking and poor diet. Research by the Health Foundation has found that 9 million more people will be living with conditions such as cancer, diabetes, dementia, kidney disease and depression by 2040. Cerny urged Wes Streeting, the health secretary, to include robust measures to improve public health in the government's forthcoming 10-year plan for the NHS. They should include targets to cut smoking, alcohol consumption and overweight, introducing minimum unit pricing of alcohol in England and extending the sugar tax to other unhealthy foods, she said. The Department of Health and Social Care did not comment directly on the findings. A spokesperson said the 10-year health plan, due next Thursday, would shift the NHS from treatment to prevention. Ministers are committed to tackling obesity through a ban on the advertising of junk food on TV before 9pm and a planned new food strategy, they said. They also cited the Tobacco and Vapes Bill, an increase in the public health grant and an extra £310m for treatment of drug and alcohol addiction as evidence of the government's action on public health.
